Clinical Trial Update: Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating a 10% triple virally reduced intravenous immunoglobulin in patients with primary immunodeficiency (agammaglobulinemia/h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agammaglobulinemia
• Hypogammaglobulinemia
• Immunodeficiency Diseases

Drugs mentioned

• intravenous immunoglobulin (IVIG) 10% triple virally reduced solution

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID), Agammaglobulinemia | Phase 2 | Status: COMPLETED